Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the company's lead drug. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback